Neuroderm Announces Nd0612h Achieves Comparable Pharmacokinetics To Duodopa In Head.
To-Head pilot pk comparison trial. Says plans to pursue regulatory development of nd0612h in european union (eu) based on pk similarity.
Says ld plasma concentrations of nd0612h in this study are in line with ld levels obtained in previous nd0612h pk studies.
Treatment with nd0612 did not raise safety and tolerability concerns. Nd0612h study is expected to enroll a total of 36 patients with advanced parkinson's disease, completion is anticipated in second half of 2016.
Source : reuters.com